Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes

Ophthalmic Research

Volumn 55, Issue 2, 2016, Pages 84-90

  Chang, Andrew A ^a,b   Broadhead, Geoffrey K ^a,b   Hong, Thomas ^a   Joachim, Nichole ^a   Syed, Adil ^a   Schlub, Timothy E ^c   Toth, Levente ^d   Peto, Tunde ^d   Zhu, Meidong ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; ATRIAL FIBRILLATION; ATROPHY; BEST CORRECTED VISUAL ACUITY; CATARACT; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FAINTNESS; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; GASTRITIS; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MALE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PIGMENT EPITHELIUM; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; PSEUDOPHACIC CYSTOID MACULAR OEDEMA; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA CYSTOID EDEMA; RETINA MACULA HEMORRHAGE; RETINAL PIGMENT EPITHELIUM ATROPHY; SPONDYLOLISTHESIS; SUBMACULAR HAEMORRHAGE; SUBRETINAL FLUID; TREATMENT RESPONSE; VARICOSIS; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIAL; INTRAVITREAL DRUG ADMINISTRATION; PHYSIOLOGY; TREATMENT OUTCOME; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84954373397     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000440886     Document Type: Article

References (19)

1. Heier JS, Brown DM, Chong V, et al: Intravitreal aflibercept (VEGF Trap-Eye) in wet agerelated macular degeneration. Ophthalmology 2012; 119: 2537-2548.
2. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.
3. Gasperini JL, Fawzi AA, Khondkaryan A, et al: Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 2012; 96: 14-20.
4. Brown DM, Chen E, Mariani A, Major JC Jr: Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology 2013; 120: 349-354.
5. Chang AA, Li H, Broadhead GK, et al: Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology 2014; 121: 188-192.
6. Tozer K, Roller AB, Chong LP, et al: Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents. Ophthalmology 2013; 120: 2029-2034.
7. de Geus SJ, Jager MJ, Luyten GP, Dijkman G: Shifting exudative age-related macular degeneration patients to ranibizumab after insufficient response to bevacizumab. Acta Ophthalmol 2013; 91:e411-e413.
8. Papadopoulos N, Martin J, Ruan Q, et al: Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012; 15: 171-185.
9. Kumar N, Marsiglia M, Mrejen S, et al: Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2013; 33: 1605-1612.
10. Bakall B, Folk JC, Boldt HC, et al: Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 2013; 156: 15-22 e1.
11. Cho H, Shah CP, Weber M, Heier JS: Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol 2013; 97: 1032-1035.
12. Broadhead GK, Hong T, Chang AA: Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration. Acta Ophthalmol 2014; 92: 713-723.
13. Age-Related Eye Disease Study (AREDS) Group: The age-related eye disease study (AREDS) system for classifying cataracts from photographs: AREDS report No 4. Am J Ophthalmol 2001; 131: 167-175.
14. Breslow NE, Clayton, DG: Approximate inference in generalized linear mixed models. J Am Stat Assoc 1993; 88: 17.
15. Rosenfeld PJ, Brown DM, Heier JS, et al: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
16. Brown DM, Kaiser PK, Michels M, et al: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
17. Rasmussen A, Bloch SB, Fuchs J, et al: A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology 2013; 120: 2630-2636.
18. Grunwald JE, Daniel E, Huang J, et al: Risk of geographic atrophy in the comparison of agerelated macular degeneration treatments trials. Ophthalmology 2014; 121: 150-161.
19. Young M, Chui L, Fallah N, et al: Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular agerelated macular degeneration. Retina 2014; 34: 1308-1315.